Announced today that it offers closed the first two tranches of a $16.
Announced today that it offers closed the first two tranches of a $16.5 million Series 3 private equity financing and a $12.5 million senior secured facility with GE Capital. Buying Series 3 private collateral financing was a new investor, Canepa Advanced Healthcare Fund, L.P., who joined existing investors PTV Sciences, AmKey Ventures and TriVentures II Fund L.P. Mr. Paul Enever from Canepa U.S., LLC, which serves as Purchase Advisor to Canepa Advanced Healthcare Fund, L.P., offers joined the Cardiva Table of Directors. Related StoriesUsing integrated molecular pathology to manage incidental pancreatic cysts: an interview with Dr Ananya DasCancer medical diagnosis improvements in England: an interview with Lucy Elliss-BrookesRE.WORK showcases potential technology and innovations in deep learning software’We are extremely pleased that Canepa Advanced Healthcare, L.P.This research allowed us to identify the specific group of patients that receive the greatest benefit from this product, said Wojciech Zareba, M.D., Ph.D., lead study writer and director of the Center Research Follow-up Program at the University of Rochester Medical Center. Our evaluation highlights the actual fact that this therapy is not equally effective in every mild heart failure individuals and was the basis of the FDA’s acceptance of the treatment only in sufferers with still left bundle branch block. Zareba’s team discovered that sufferers with LBBB who received CRT-D therapy got a substantial 53 % decrease in the chance of a heart failure event, such as for example being hospitalized with center failure symptoms, or death, compared to LBBB sufferers who just received an implantable cardioverter defibrillator .